Work Here?
Overview
Treeline Biosciences develops proprietary therapies for cancer and other serious diseases by conducting in-depth R&D across biology, chemistry, protein sciences, and computational science. Its product work involves discovering and optimizing drug candidates, then licensing these therapies to larger pharmaceutical companies or selling them to healthcare providers, with support from CRO collaborations to speed development. The company differentiates itself through a balanced mix of in-house research and external partnerships, a robust IP strategy, and a team that blends experienced biotech veterans with new talent, all backed by funding from KKR to scale operations. Its goal is to build a sustainable, long-term pipeline of treatments that can reach patients while expanding capabilities and partnerships in the biotech ecosystem.
About Treeline Biosciences
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
Series A
Total Funding
$1.1B
Headquarters
Stamford, Connecticut
Founded
2021
Get referred to Treeline Biosciences
See people who can refer or advise you
Simplify's Take
What believers are saying
- Phase 1 data from the first three programs is expected in 2027.
- TLN-499 is slated to enter the clinic in 2026, adding another catalyst.
- More than $900 million in combined cash supports runway into 2029.
What critics are saying
- All therapies remain investigational, so Treeline has no approved product revenue.
- TLN-372 faces intense competition in crowded KRAS oncology programs.
- TLN-254 inherits development risk from Hengrui's prior Phase 2-only progress.
What makes Treeline Biosciences unique
- Treeline combines internally discovered assets with in-licensed programs from Jiangsu Hengrui Pharmaceuticals.
- Its pipeline spans small molecules, protein degraders, and targeted therapy antibody-drug conjugates.
- The company is advancing oncology programs while expanding into neurology and immunology.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$1.1B
Above
Industry Average
Funded Over
4 Rounds
Industry standards
Benefits
Health Insurance
401(k) Retirement Plan
Remote Work Options
Flexible Work Hours
Paid Vacation
Paid Holidays
Hybrid Work Options
Wellness Program
Mental Health Support
Phone/Internet Stipend
Home Office Stipend
Professional Development Budget
Conference Attendance Budget
Stock Options
Company Equity
Family Planning Benefits
Fertility Treatment Support
Adoption Assistance
Childcare Support
Elder Care Support
Wellness Program
Gym Membership
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↓ -2%2 year growth
↑ 0%Josh bilenker's Treeline Biosciences gets another $200M, bringing funding to $1.1B.
Treeline Biosciences announced the start of Phase 1 trials for three programs: TLN-121 (BCL6 degrader) and TLN-254 (EZH2 inhibitor) for lymphoma, and TLN-372 (pan-KRAS inhibitor) for KRAS-mutated cancers. They also secured a $200 million Series A extension, totaling $1.1 billion in funding. CEO Josh Bilenker highlighted their aim to create a leading biopharma company with innovative cancer treatments.
Treeline Biosciences commences Phase 1 trials and secures $200 million Series A extension funding.
Treeline Biosciences, a drug discovery startup based in Watertown, MA, has secured $421 million in October's largest fundraising round.
Treeline Biosciences, based in Watertown, raised the largest venture capital round by a Massachusetts biotech in 2024, securing $422 million. Co-founded by Joshua Bilenker and Jeffrey Engelman, the company focuses on challenging molecular targets in oncology.
Treeline Biosciences is Hiring for 12 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Treeline Biosciences
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
Series A
Total Funding
$1.1B
Headquarters
Stamford, Connecticut
Founded
2021
Treeline Biosciences is Hiring for 12 Jobs on Simplify!
Find jobs on Simplify and start your career today